StrataGraft Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing incidence of burn injuries, advancements in tissue engineering research, rising adoption of allogeneic skin substitutes, growing investments in regenerative medicine, improved clinical outcomes in burn management.

The growth in the forecast period can be attributed to expansion of regenerative medicine approvals, increasing demand for advanced wound care products, rising investments in bioengineered tissue platforms, growing focus on outpatient burn treatment solutions, continued innovation in skin substitute technologies. Major trends in the forecast period include increasing adoption of bioengineered skin substitutes, rising demand for advanced burn care solutions, growing focus on regenerative wound healing therapies, expansion of collagen-based scaffold technologies, enhanced emphasis on reduced autograft dependency.

The rising incidence of chronic wounds and burn injuries is expected to drive the growth of the Stratagraft market going forward. Chronic wounds are long-lasting injuries that fail to heal within the usual timeframe due to factors such as diabetes, poor circulation, or pressure ulcers, while burn injuries result from exposure to thermal, chemical, or electrical agents and often require advanced medical care for repair. The increase in these conditions is driven by factors including diabetes, obesity, an aging population, industrial accidents, and limited access to preventive care in many regions. Stratagraft provides an advanced treatment option for chronic wounds and burn injuries by offering a bioengineered alternative to traditional skin grafts, promoting effective wound healing while reducing the need for donor site procedures. For instance, in October 2023, the World Health Organization (WHO) reported that globally, burns cause about 180,000 deaths annually, mostly in low- and middle-income countries. In the United States, approximately 410,000 burn injuries occurred in 2023, with around 40,000 requiring hospitalization, highlighting the ongoing public health impact of burn injuries. Therefore, the rising incidence of chronic wounds and burn injuries is driving the growth of the Stratagraft market.

Increasing healthcare spending is expected to further propel the Stratagraft market. Healthcare spending includes the financial resources allocated by governments, individuals, businesses, and other entities toward healthcare services, products, and treatments. Rising healthcare spending is driven by aging populations, the increasing prevalence of chronic diseases, technological advancements, and growing demand for medical care. This spending supports Stratagraft by funding research and development for advanced wound care therapies, improving patient access to treatment for severe burns and chronic wounds, and ensuring insurance coverage for long-term management, thereby increasing treatment availability and affordability. For example, in November 2023, the Canadian Institute for Health Information reported that total health spending in Canada was projected to rise by 2.8% in 2023, following a 1.5% increase in 2022. Therefore, increased healthcare spending is driving the growth of the Stratagraft market.

The growing number of clinical trials is expected to propel the Stratagraft market further. Clinical trials are structured studies conducted to evaluate the safety, efficacy, and potential side effects of medical treatments in humans. An increasing number of trials reflects advances in science, the complexity of healthcare needs, and a broader scope of medical research. Clinical trials support Stratagraft by generating critical evidence on its safety and effectiveness in treating severe burn injuries, validating its ability to accelerate skin regeneration, reduce complications, and inform regulatory approval and clinical adoption. For instance, in December 2024, the Association of the British Pharmaceutical Industry reported that industry-sponsored clinical trials initiated in the UK increased from 411 in 2022 to 426 in 2023, reflecting growing R&D activity that supports innovation in patient care and generates additional revenue for the NHS. Therefore, the rising number of clinical trials is driving the growth of the Stratagraft market.

Major companies operating in the stratagraft market are Mallinckrodt Pharmaceuticals plc.

North America was the largest region in the stratagraft market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stratagraft market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stratagraft market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the stratagraft market by increasing costs associated with imported collagen scaffolds, bioprocessing equipment, cell culture materials, and specialized manufacturing consumables used in bioengineered skin production. Healthcare providers and manufacturers in North America and Europe are most affected due to reliance on cross-border biomedical supply chains, while Asia-Pacific faces cost pressures on raw material sourcing. These tariffs are contributing to higher production costs and pricing pressures for advanced skin substitutes. However, they are also encouraging localized biomanufacturing, domestic sourcing of biomaterials, and regional expansion of tissue engineering production capabilities.

The stratagraft market research report is one of a series of new reports that provides stratagraft market statistics, including stratagraft industry global market size, regional shares, competitors with a stratagraft market share, detailed stratagraft market segments, market trends and opportunities, and any further data you may need to thrive in the stratagraft industry. This stratagraft market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

StrataGraft is a bioengineered, allogeneic skin substitute used to treat deep partial-thickness burns and other complex skin defects. It consists of both dermal and epidermal layers, created from human keratinocytes and dermal fibroblasts cultured on a collagen scaffold.

The primary indications for StrataGraft include thermal burns and full-thickness burns. Thermal burns are injuries caused by heat, such as flames, steam, or hot surfaces, which damage the skin and underlying tissues. StrataGraft is available as allogeneic cultured keratinocytes and dermal fibroblasts and is used by end users including hospitals, specialized wound care centers, and outpatient care facilities.

The stratagraft market consists of sales of bioengineered skin substitutes, dermal replacement Grafts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.